<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CABAZITAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CABAZITAXEL" rxcui="996051">
<ATC code="L01CD04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the concentrations of the cytotoxic by increase of its metabolism by the inducer, with risk of lower effectiveness</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>107-CABAZITAXEL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="CABAZITAXEL" rxcui="996051">
<ATC code="L01CD04" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzymatic inducer</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the cabazitaxel during the treatment with the enzymatic inhibitor.</COMMENT>
</INTERACTION>
</INTERACTIONS>
